In preclinical studies on mice further validated on CRC patients, Dosset and collaborators [69] noticed an increase in the expression of PD-L1 and a significant infiltration of CD8 T cells in the TME of patients who underwent treatment with the FOLFOX regimen. The gene discussed is CD8A; the disease is colorectal carcinoma.